Literature DB >> 23419139

In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice.

Hiroshi Yamazaki1, Hiroshi Suemizu, Norie Murayama, Masahiro Utoh, Norio Shibata, Masato Nakamura, F Peter Guengerich.   

Abstract

In vivo drug interactions of the teratogen thalidomide with the model cytochrome P450 (P450) 3A substrate midazolam were investigated in mice with humanized livers. The clearance of midazolam (administered intravenously, 10 mg kg(-1)) in chimeric mice was enhanced by orally co-administered thalidomide (100 mg kg(-1)). A larger area under the curve of the major metabolite 1'-hydroxymidazolam (1.7-fold) was obtained with thalidomide because of the heterotropic cooperativity of human P450 3A enzymes. A larger area under the curve of the minor metabolite 4-hydroxymidazolam (3.5-fold) was seen with daily pretreatment with thalidomide for 3 days, presumably because of human P450 3A induction. These results demonstrate that livers of humanized mice mediate drug interactions of thalidomide and suggest interactions of therapeutic agents during therapies with thalidomide.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23419139      PMCID: PMC4049203          DOI: 10.1021/tx400008g

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  11 in total

1.  In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Makiko Shimizu; Sho Igaya; Norio Shibata; Masato Nakamura; Goutam Chowdhury; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-01-25       Impact factor: 3.739

2.  Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Authors:  Goutam Chowdhury; Norie Murayama; Yusuke Okada; Yasuhiro Uno; Makiko Shimizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

3.  Thalidomide revisited: pharmacology and clinical applications.

Authors:  L Calabrese; K Resztak
Journal:  Expert Opin Investig Drugs       Date:  1998-12       Impact factor: 6.206

4.  The reconstituted 'humanized liver' in TK-NOG mice is mature and functional.

Authors:  Masami Hasegawa; Kenji Kawai; Tetsuya Mitsui; Kenji Taniguchi; Makoto Monnai; Masatoshi Wakui; Mamoru Ito; Makoto Suematsu; Gary Peltz; Masato Nakamura; Hiroshi Suemizu
Journal:  Biochem Biophys Res Commun       Date:  2011-01-14       Impact factor: 3.575

5.  The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species.

Authors:  H Schumacher; R L Smith; R T Williams
Journal:  Br J Pharmacol Chemother       Date:  1965-10

6.  Hydroxylated metabolites of thalidomide: formation in-vitro and in-vivo in man.

Authors:  T Eriksson; S Björkman; B Roth; H Björk; P Höglund
Journal:  J Pharm Pharmacol       Date:  1998-12       Impact factor: 3.765

7.  In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Sho Igaya; Makiko Shimizu; Norio Shibata; Masato Nakamura; Goutam Chowdhury; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2011-02-07       Impact factor: 3.739

8.  Thalidomide: the tragedy of birth defects and the effective treatment of disease.

Authors:  James H Kim; Anthony R Scialli
Journal:  Toxicol Sci       Date:  2011-04-19       Impact factor: 4.849

Review 9.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

10.  Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.

Authors:  C B Trapnell; S R Donahue; J M Collins; D A Flockhart; D Thacker; D R Abernethy
Journal:  Clin Pharmacol Ther       Date:  1998-12       Impact factor: 6.875

View more
  11 in total

1.  Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics.

Authors:  Eiko Suzuki; Kumiko Koyama; Daisuke Nakai; Ryoya Goda; Hiroshi Kuga; Kan Chiba
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

Review 2.  P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.

Authors:  Karl-Dimiter Bissig; Weiguo Han; Mercedes Barzi; Nataliia Kovalchuk; Liang Ding; Xiaoyu Fan; Francis P Pankowicz; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

3.  Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.

Authors:  Makiko Shimizu; Hiroshi Suemizu; Marina Mitsui; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Xenobiotica       Date:  2016-11-16       Impact factor: 1.908

4.  Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Authors:  Anna L Blobaum; Thomas M Bridges; Frank W Byers; Mark L Turlington; Margrith E Mattmann; Ryan D Morrison; Claire Mackie; Hilde Lavreysen; José M Bartolomé; Gregor J Macdonald; Thomas Steckler; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2013-09-03       Impact factor: 3.922

5.  Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.

Authors:  Norie Murayama; Hiroshi Suemizu; Shotaro Uehara; Takashi Kusama; Marina Mitsui; Yusuke Kamiya; Makiko Shimizu; F Peter Guengerich; Hiroshi Yamazaki
Journal:  J Toxicol Sci       Date:  2018       Impact factor: 2.196

6.  Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4.

Authors:  Ilia G Denisov; Yelena V Grinkova; Mark A McLean; Tyler Camp; Stephen G Sligar
Journal:  Biomolecules       Date:  2022-06-20

7.  Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Authors:  Norie Murayama; Rinie van Beuningen; Hiroshi Suemizu; Christiane Guguen Guillouzo; Norio Shibata; Kanako Yajima; Masahiro Utoh; Makiko Shimizu; Christophe Chesné; Masato Nakamura; F Peter Guengerich; René Houtman; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2014-02-05       Impact factor: 3.739

Review 8.  Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Marina Mitsui; Makiko Shimizu; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-05       Impact factor: 3.739

9.  Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice.

Authors:  Sayako Nishiyama; Hiroshi Suemizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2015-10-26       Impact factor: 3.739

10.  Self-disproportionation of enantiomers of thalidomide and its fluorinated analogue via gravity-driven achiral chromatography: mechanistic rationale and implications.

Authors:  Mayaka Maeno; Etsuko Tokunaga; Takeshi Yamamoto; Toshiya Suzuki; Yoshiyuki Ogino; Emi Ito; Motoo Shiro; Toru Asahi; Norio Shibata
Journal:  Chem Sci       Date:  2014-10-30       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.